Psychiatry and Neurology, Neurology · Englewood, CO
NPI
1447343751
Since 2006
Specialty
Psychiatry and Neurology, Neurology
Code 2084N0400X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
701 E. Hampden Ave, Suite 510
Englewood, CO, 80013
Phone (303) 357-5455
Groups this clinician bills Medicare through
Medicare paid, 2024
$360K
52,084 services
Medicare patients, 2024
250
Average age 72
Drug cost, 2024
$2.3M
4,548 prescriptions
Company payments, 2025
$9,870
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Rajeev Kumar was code J0585 (injection, onabotulinumtoxina, 1 unit), 46,632 times for 52 patients. In total Rajeev Kumar billed 52,084 services in 29 codes, and Medicare paid $360K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-10-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0585 Injection, onabotulinumtoxina, 1 unit | Office | 46,632 | 52 | $4.92 | $229K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 294 | 169 | $11.69 | $3,438 |
| 99215 Office E&M - Established | Office | 190 | 125 | $127.89 | $24K |
| 99214 Office E&M - Established | Office | 168 | 103 | $83.20 | $14K |
| 95874 Musculoskeletal | Office | 153 | 54 | $61.50 | $9,409 |
| 99213 Office E&M - Established | Office | 129 | 54 | $65.11 | $8,399 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 129 | 58 | $24.75 | $3,192 |
| 64616 Musculoskeletal | Office | 120 | 38 | $133.52 | $16K |
| 64612 Musculoskeletal | Office | 64 | 26 | $150.65 | $9,641 |
| 99205 Office E&M - New | Office | 50 | 50 | $162.17 | $8,108 |
| 64646 Musculoskeletal | Office | 43 | 16 | $68.26 | $2,935 |
| 95970 Electrical Nerve Conductivity | Office | 35 | 22 | $13.92 | $487 |
| 64642 Musculoskeletal | Office | 28 | 12 | $96.29 | $2,696 |
| 95983 Electrical Nerve Conductivity | Office | 23 | 11 | $39.25 | $903 |
| 96138 Behavioral Health Services | Office | 12 | 12 | $28.21 | $339 |
By year: 2022 $478K for 67,791 services; 2023 $452K for 61,887 services; 2024 $360K for 52,084 services.
Medicare prescription drug claims, 2024
In 2024, the drug Rajeev Kumar prescribed most often to Medicare patients was Carbidopa-Levodopa (Carbidopa/Levodopa), with 818 prescriptions and refills. In total Rajeev Kumar wrote 4,548 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Carbidopa-Levodopa Carbidopa/Levodopa | 818 | 1,858 | 208 | $32K |
| Rasagiline Mesylate Generic | 335 | 793 | 81 | $59K |
| Clonazepam Generic | 326 | 482 | 54 | $2,868 |
| Carbidopa-Levodopa Er Carbidopa/Levodopa | 285 | 621 | 77 | $14K |
| Rytary Carbidopa/Levodopa | 266 | 481 | 40 | $450K |
| Amantadine Amantadine Hcl | 238 | 515 | 65 | $20K |
| Pramipexole Dihydrochloride Pramipexole Di-Hcl | 189 | 415 | 42 | $6,999 |
| Venlafaxine Hcl Er Venlafaxine Hcl | 165 | 265 | 25 | $3,807 |
| Rivastigmine Generic | 152 | 189 | 35 | $27K |
| Selegiline Hcl Generic | 120 | 228 | 24 | $13K |
| Propranolol Hcl Er Propranolol Hcl | 91 | 235 | 23 | $5,469 |
| Nuplazid Pimavanserin Tartrate | 87 | 95 | 13 | $457K |
| Entacapone Generic | 84 | 147 | 23 | $16K |
| Gabapentin Generic | 67 | 152 | 21 | $1,921 |
| Clozapine Generic | 63 | 63 | Under 11 | $5,103 |
Brand drugs: 921 claims; generic drugs: 3,627 claims; opioid claims: 15.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Rajeev Kumar $9,870 ($9,870 in general payments such as food, travel and fees) from 18 companies. The largest payer was Abbvie Inc. with $9,162.
| Company | Payments | Amount |
|---|---|---|
| Abbvie Inc. ABBV | 34 | $9,162 |
| MDD US Operations, LLC | 8 | $174 |
| Neurocrine BioSciences, Inc. NBIX | 1 | $167 |
| ACADIA Pharmaceuticals Inc ACAD | 5 | $114 |
| Merz Pharmaceuticals, LLC | 3 | $57.12 |
| Revance Therapeutics, Inc. | 1 | $51.1 |
| Abbott Laboratories ABT | 2 | $44.22 |
| Medtronic, Inc. MDT | 2 | $39.27 |
| Teva Pharmaceuticals USA, Inc. TEVA | 1 | $29.69 |
| Amneal Pharmaceuticals LLC AMRX | 1 | $16.61 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.